Voices
Paolo Ciracì
Paolo Ciracì/X

Paolo Ciracì: Final Results of the PARERE Study

Paolo Ciracì, Medical Oncology Resident at the University Hospital of Pisa, shared a post on X about a recent article he and his colleagues co-authored, published in Annals Oncology:

“Final results of the PARERE study in Annals Oncology

  • 428 mCRC pts screened via liquid biopsy for anti-EGFR re-tx
  • >⅓ RAS and/or BRAF mut in ctDNA
  •  No OS diff (pani→rego vs rego→pani)
  •  Higher ORR, DCR & PFS with pani, regardless of sequence”

Title: Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

Authors: P. Ciracì, M.M. Germani, F. Pietrantonio, P. Manca, S. Lonardi, A. Busico, F. Bergamo, V. Burgio, F. Mannavola, S. Di Donato, E. Fenocchio, F. Palermo, I. Capone, M.C. De Grandis, N. Pella, M. Scartozzi, L. Antonuzzo, A. Passardi, M. Claravezza, L. Salvatore, S. Tamberi, G. Randon, E. Conca, V. Conca, C. Antoniotti, R. Moretto, G. Masi, L. Boni, D. Rossini, C. Cremolini

Read the Full Article on Annals Oncology

Paolo Ciracì: Final Results of the PARERE Study

More posts featuring Paolo Ciracì.

A. Busico A. Passardi C. Antoniotti C. Cremolini cancer D. Rossini E. Conca E. Fenocchio F. Bergamo F. Mannavola F. Palermo F. Pietrantonio G. Masi G. Randon I. Capone L Boni L. Antonuzzo L. Salvatore M. Claravezza M. M. Germani M. Scartozzi M.C. De Grandis N. Pella OncoDaily Oncology P. Ciracì P. Manca Paolo Ciracì PARERE study R. Moretto S. Di Donato S. Lonardi S. Tamberi V. Burgio V. Conca